Evidence map›Paper›PMID 38031155›Full record

ArticleAntimicrobial resistance and infection control2023

Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up.

Claudia Recanatini, Corine H GeurtsvanKessel, Suzan D Pas, Els M Broens, Martje Maas, Rosa van Mansfeld, Anne J G Mutsaers-van Oudheusden, Miranda van Rijen, Emile F Schippers, Arjan Stegeman and 11 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial resistance and infection control, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 1 country.

Claudia RecanatiniJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. claudia.recanatini@gmail.com.
Corine H GeurtsvanKesselViroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands.
Suzan D PasMicrovida Laboratory for Medical Microbiology, Bravis Hospital, Roosendaal, The Netherlands.
Els M BroensDepartment Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Martje MaasDepartment of Internal Medicine, Bernhoven Hospital, Uden, The Netherlands.
Rosa van MansfeldDepartment of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Anne J G Mutsaers-van OudheusdenDepartment of Infection Control, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
Miranda van RijenDepartment of Infection Control, Amphia Hospital, Breda, The Netherlands.
Emile F SchippersDepartment of Internal Medicine, Haga Hospital, The Hague, The Netherlands.
Arjan StegemanDepartment of Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Adriana TamiDepartment of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Karin Ellen VeldkampDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Hannah VisserDepartment of Internal Medicine, Beatrix Hospital, Gorinchem, The Netherlands.
Andreas VossDepartment of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Marjolijn C A Wegdam-BlansCatharina Hospital, Eindhoven, The Netherlands.
Heiman F L WertheimRadboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Peter C WeverDepartment of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
Marion P G KoopmansViroscience Department, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jan A J W KluytmansJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Marjolein F Q Kluytmans-van den BerghJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
COCON Study Group
Utrecht University · NLUniversity Medical Center Groningen · NLRadboud University Nijmegen · NLAmphia Ziekenhuis · NLAmsterdam University Medical Centers · NLElisabeth-TweeSteden Ziekenhuis · NLErasmus MC · NLBeatrix Kinderziekenhuis · NLBravis Ziekenhuis · NLCanisius-Wilhelmina Ziekenhuis · NLHaga Hospital · NLJeroen Bosch Ziekenhuis · NLLeiden University Medical Center · NLUniversity Medical Center Utrecht · NLZiekenhuis Bernhoven · NL

Funding

ZonMw project number 10150062010004
6 · The paper itself

Abstract

backgroundWe aimed to estimate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence and describe its determinants and associated symptoms among unvaccinated healthcare workers (HCWs) after the first wave of the pandemic.

methodsHCWs from 13 Dutch hospitals were screened for antibodies against the spike protein of SARS-CoV-2 in June-July 2020 and after three months. Participants completed a retrospective questionnaire on determinants for occupational and community exposure to SARS-CoV-2 and symptoms suggestive of COVID-19 experienced since January 2020. The seroprevalence was calculated per baseline characteristic and symptom at baseline and after follow-up. Adjusted odds ratios (aOR) for seropositivity were determined using logistic regression.

resultsAmong 2328 HCWs, 323 (13.9%) were seropositive at enrolment, 49 of whom (15%) reported no previous symptoms suggestive of COVID-19. During follow-up, only 1% of the tested participants seroconverted. Seroprevalence was higher in younger HCWs compared to the mid-age category (aOR 1.53, 95% CI 1.07-2.18). Nurses (aOR 2.21, 95% CI 1.34-3.64) and administrative staff (aOR 1.87, 95% CI 1.02-3.43) had a higher seroprevalence than physicians. The highest seroprevalence was observed in HCWs in the emergency department (ED) (aOR 1.79, 95% CI 1.10-2.91), the lowest in HCWs in the intensive, high, or medium care units (aOR 0.47, 95% CI 0.31-0.71). Chronic respiratory disease, smoking, and having a dog were independently associated with a lower seroprevalence, while HCWs with diabetes mellitus had a higher seroprevalence. In a multivariable model containing all self-reported symptoms since January 2020, altered smell and taste, fever, general malaise/fatigue, and muscle aches were positively associated with developing antibodies, while sore throat and chills were negatively associated.

conclusionsThe SARS-CoV-2 seroprevalence in unvaccinated HCWs of 13 Dutch hospitals was 14% in June-July 2020 and remained stable after three months. A higher seroprevalence was observed in the ED and among nurses, administrative and young staff, and those with diabetes mellitus, while a lower seroprevalence was found in HCWs in intensive, high, or medium care, and those with self-reported lung disease, smokers, and dog owners. A history of altered smell or taste, fever, muscle aches and fatigue were independently associated with the presence of SARS-CoV-2 antibodies in unvaccinated HCWs.

Indexed as

Antibodies, ViralCOVID-19Cross-Sectional StudiesDiabetes MellitusFatigueFollow-Up StudiesHealth PersonnelHospitalsHumansNetherlandsPainProspective StudiesRetrospective StudiesSeroepidemiologic StudiesAntibodies, ViralAntibodiesCOVID-19Healthcare workerRisk factorSARS-CoV-2Self-reported symptomsSeroprevalence

Identifiers

PMID38031155
PMCPMC10688070
OpenAlexW4389132489

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.